High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer
暂无分享,去创建一个
J. Mackey | Sunita Ghosh | S. Damaraju | R. Lai | G. Bigras | Chengsheng Wu | A. Alshareef | S. Sabri | B. Abdulkarim | K. Jung | N. Gupta | H. Alqahtani
[1] E. Li,et al. The PI3K/AKT/c‐MYC Axis Promotes the Acquisition of Cancer Stem‐Like Features in Esophageal Squamous Cell Carcinoma , 2016, Stem cells.
[2] P. Swanson,et al. New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[3] G. Ball,et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours , 2016, British Journal of Cancer.
[4] J. Lieberman,et al. The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation , 2015, Cell reports.
[5] N. Kneteman,et al. Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter , 2015, Oncotarget.
[6] Qiu-ying Liu,et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway , 2015, Molecular Cancer.
[7] K. Gopal,et al. Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays , 2014, Breast Cancer Research.
[8] J. Dopazo,et al. The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential , 2014, Front. Oncol..
[9] S. Thorgeirsson,et al. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. , 2014, Cancer research.
[10] M. Ando,et al. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] C. Creighton,et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.
[12] M. Glukhova,et al. Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis , 2013, Molecular Cancer.
[13] Phillip Owens,et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. , 2013, Cancer research.
[14] Yupo Ma,et al. Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. , 2012, Cellular signalling.
[15] M. Hitt,et al. Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma , 2012, Blood Cancer Journal.
[16] M. Glukhova,et al. The Proto‐Oncogene Myc Is Essential for Mammary Stem Cell Function , 2012, Stem cells.
[17] Hui-Kuan Lin,et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.
[18] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[19] Marc E. Lenburg,et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.
[20] Shuji Ogino,et al. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. , 2012, Cancer research.
[21] Y. Hoki,et al. Crucial Role of C‐Myc in the Generation of Induced Pluripotent Stem Cells , 2011, Stem cells.
[22] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[23] J. Mackey,et al. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer , 2011, Breast Cancer Research and Treatment.
[24] E. Henson,et al. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer , 2011, Oncogene.
[25] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[26] Olufunmilayo I Olopade,et al. MYC and Breast Cancer. , 2010, Genes & cancer.
[27] R. Huang,et al. Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.
[28] David J. Nott,et al. Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup , 2009, PloS one.
[29] Hui Wang,et al. c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.
[30] R. Eisenman,et al. Myc's broad reach. , 2008, Genes & development.
[31] Susan G Hilsenbeck,et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.
[32] Robin L. Jones,et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study , 2006, Journal of Clinical Pathology.
[33] B. Lüscher,et al. The Ins and Outs of MYC Regulation by Posttranslational Mechanisms* , 2006, Journal of Biological Chemistry.
[34] M. Huang,et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.
[35] Harikrishna Nakshatri,et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.
[36] Kathryn A. O’Donnell,et al. The c-Myc target gene network. , 2006, Seminars in cancer biology.
[37] Ziqiu Wang,et al. Phosphorylation regulates Myc expression via prolonged activation of the mitogen‐activated protein kinase pathway , 2006, Journal of cellular physiology.
[38] P. Schirmacher,et al. c-myc Amplifications in primary breast carcinomas and their local recurrences , 2006, Journal of Clinical Pathology.
[39] Danila Coradini,et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.
[40] Peter Schraml,et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.
[41] M. J. van de Vijver,et al. Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.
[42] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] C. Schlotter,et al. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.
[44] Stella Pelengaris,et al. c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.
[45] H. Niwa,et al. Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. , 2002, Nucleic acids research.
[46] A. Karmoliński,et al. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. , 2001, Clinical biochemistry.
[47] B. Trock,et al. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.
[48] D. Persons,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.